Vildagliptin 50 MG

• Recruiting NCT NCT03925701

  Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

  Not yet reported Sherief Abd-Elsalam 120 participants Est. completion 2028-12 1 site Stand-alone
  Other conditions: dm
  View official trial listing →
• Recruiting NCT NCT06142656

  Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

  Not yet reported, Not yet reported October 6 University 60 participants Est. completion 2026-02-01 1 site
  Other conditions: Poly Cystic Ovary Syndrome
  View official trial listing →
• Completed NCT NCT00099853

  Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

  Not yet reported Novartis Pharmaceuticals 362 participants Est. completion 2008-01 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00138554

  Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

  Not yet reported Novartis 318 participants Est. completion 2006-07 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00368134

  To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

  Not yet reported Novartis 370 participants 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00616811

  Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

  Not yet reported Novartis 148 participants Est. completion 2010-10 79 sites
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT00633997

  Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

  Not yet reported, Not yet reported Novartis 22 participants 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00765830

  Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

  Not yet reported Novartis 349 participants Est. completion 2011-04 90 sites
  Type 2 diabetes Other conditions: Renal Insufficiency
  View official trial listing →
• Completed NCT NCT00770081

  Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

  Not yet reported Novartis 75 participants Est. completion 2011-04 87 sites
  Type 2 diabetes Other conditions: Renal Insufficiency
  View official trial listing →
• Completed NCT NCT00818571

  Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

  Not yet reported, Not yet reported Novartis Pharmaceuticals 96 participants 1 site Stand-alone
  Other conditions: Renal Impairment, Diabetes
  View official trial listing →
• Completed NCT NCT00822211

  Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

  Not yet reported Novartis 404 participants Est. completion 2009-12 17 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Withdrawn NCT NCT00936234

  Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).

  Not yet reported, Not yet reported Johann Wolfgang Goethe University Hospital Est. completion 2013-05 1 site
  Other conditions: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
  View official trial listing →
• Completed NCT NCT00975065

  Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

  Not yet reported Handok Inc. 266 participants Est. completion 2012-04 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT00980356

  Vildagliptin in New Onset Diabetes After Transplantation

  Not yet reported Medical University of Vienna 32 participants Est. completion 2012-12 1 site
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT01147276

  Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

  Not yet reported Lund University 28 participants Est. completion 2011-12 1 site
  Other conditions: Diabetes, Hypoglycemia
  View official trial listing →
• Completed NCT NCT01219400

  Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes

  Not yet reported Lund University 28 participants Est. completion 2013-12 1 site
  Other conditions: Diabetes
  View official trial listing →
• Completed NCT NCT01233622

  Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

  Not yet reported Novartis 317 participants Est. completion 2011-11 55 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01404676

  The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

  Not yet reported Samsung Medical Center 34 participants Est. completion 2012-05 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01426802

  Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

  Not yet reported Novartis Pharmaceuticals 150 participants Est. completion 2011-04 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01472432

  DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes

  Not yet reported University of Campania Luigi Vanvitelli 106 participants Est. completion 2016-01 1 site Stand-alone
  Other conditions: Chronic Foot Ulcers
  View official trial listing →
• Completed NCT NCT01497522

  Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

  Not yet reported Novartis Pharmaceuticals 183 participants Est. completion 2013-02 20 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01537120

  Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

  Not yet reported Merck Sharp & Dohme LLC 25 participants Est. completion 2012-10 Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01541956

  Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

  Not yet reported Novartis Pharmaceuticals 3091 participants Est. completion 2013-12 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT01565096

  Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

  Not yet reported ikfe-CRO GmbH 44 participants 1 site Stand-alone
  Other conditions: Diabetes Mellitus Type II
  View official trial listing →
• Completed NCT NCT01582230

  Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

  Not yet reported Novartis Pharmaceuticals 293 participants Est. completion 2013-05 21 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01582243

  Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

  Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2015-09 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01582308

  A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

  Not yet reported Merck Sharp & Dohme LLC 22 participants Est. completion 2012-12-14 Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01679899

  Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability

  Not yet reported Centro de Diabetes Curitiba Ltda 56 participants Est. completion 2015-10 1 site Stand-alone
  Type 2 diabetes Other conditions: Menopause, Osteoporosis, Osteopenia
  View official trial listing →
• Completed NCT NCT01811485

  Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

  Not yet reported Novartis Pharmaceuticals 171 participants Est. completion 2014-02 30 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT01862263

  Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

  Not yet reported Novartis Pharmaceuticals 191 participants Est. completion 2015-07 13 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01871558

  Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

  Not yet reported Novartis Pharmaceuticals 42 participants Est. completion 2015-02 19 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Terminated NCT NCT01910441

  Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

  Not yet reported Novartis Pharmaceuticals 95 participants Est. completion 2014-09 Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT01963130

  Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study

  Bezmialem Vakif University 97 participants Est. completion 2013-07 1 site
  Other conditions: Drug Mechanism, Drug Usage
  View official trial listing →
• Completed NCT NCT02002221

  Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

  Not yet reported Novartis Pharmaceuticals 156 participants Est. completion 2015-02 31 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02176681

  A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

  Not yet reported University Hospital, Strasbourg, France 70 participants Est. completion 2017-10 13 sites Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02475070

  Vildagliptin Versus Dapagliflozin on Glucagon

  Not yet reported Lund University 28 participants Est. completion 2017-06 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT02749032

  Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion

  Not yet reported Michael A. Nauck 24 participants 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT03253562

  Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

  Not yet reported MTI University 120 participants Est. completion 2017-08-01 1 site
  Other conditions: Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
  View official trial listing →
• Completed NCT NCT03500900

  Vildagliptin on Gastric Accommodation

  Not yet reported Universitaire Ziekenhuizen KU Leuven 20 participants Est. completion 2017-01-01 Stand-alone
  Other conditions: Healthy
  View official trial listing →
• Completed NCT NCT03693560

  Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

  Not yet reported Damanhour University 80 participants Est. completion 2019-10-10 1 site Stand-alone
  Cardiovascular diseaseType 2 diabetes
  View official trial listing →
• Completed NCT NCT03819127

  Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment

  Not yet reported University of Catania 60 participants Est. completion 2016-09 Stand-alone
  Other conditions: Mild Cognitive Impairment
  View official trial listing →
• Completed NCT NCT03918148

  Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

  University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT04300790

  Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

  Not yet reported MedSIR 69 participants Est. completion 2025-03-16 19 sites Stand-alone
  Other conditions: Breast Cancer
  View official trial listing →
• Withdrawn NCT NCT04410341

  The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

  Not yet reported, Not yet reported Sadat City University Est. completion 2024-12-01 1 site Stand-alone
  Other conditions: Major Depressive Disorder
  View official trial listing →
• Withdrawn NCT NCT04761861

  Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

  Not yet reported Sadat City University Est. completion 2025-12-31 1 site Stand-alone
  Other conditions: Schizophrenia, Dyslipidemias
  View official trial listing →
• Completed NCT NCT04916093

  Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

  Not yet reported Beni-Suef University 60 participants Est. completion 2020-12-15 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Status unknown NCT NCT05102149

  Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

  Not yet reported PegBio Co., Ltd. 672 participants Est. completion 2025-04 42 sites
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT05329844

  The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

  Not yet reported AET Laboratories Private Limited 66 participants Est. completion 2015-04 Stand-alone
  Other conditions: Diabetes Mellitus
  View official trial listing →
• Completed NCT NCT05329857

  The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

  Not yet reported AET Laboratories Private Limited 60 participants Est. completion 2016-03
  Other conditions: To Determine Bioequivalence Under Fed Conditions
  View official trial listing →
• Active, not recruiting NCT NCT05366868

  Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

  Not yet reported National Center for Global Health and Medicine, Japan 567 participants Est. completion 2027-03-31 1 site
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06068686

  Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

  Not yet reported Damanhour University 70 participants Est. completion 2024-12-01 1 site Stand-alone
  Type 2 diabetes
  View official trial listing →
• Completed NCT NCT06313008

  Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

  Not yet reported Damanhour University 120 participants Est. completion 2024-10-10 1 site Stand-alone
  Cardiovascular diseaseType 2 diabetes
  View official trial listing →
• Active, not recruiting NCT NCT06889909

  Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

  Not yet reported Lahore General Hospital 102 participants Est. completion 2025-06-15 1 site
  Type 2 diabetes
  View official trial listing →
• Active, not recruiting NCT NCT06913101

  Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

  Not yet reported PNS Hafeez - Naval Hospital 102 participants Est. completion 2025-05-15 1 site
  Type 2 diabetes
  View official trial listing →
• Not yet recruiting NCT NCT06951334

  Clinical Trial of Vildagliptin in Early Parkinson's Disease

  Not yet reported First Affiliated Hospital, Sun Yat-Sen University 66 participants Est. completion 2026-12-31 Stand-alone
  Other conditions: Parkinson's Disease
  View official trial listing →
• Not yet recruiting NCT NCT07811011

  Efficacy of Dapagliflozin Versus Metformin in Patients With Polycystic Ovary Syndrome

  Not yet reported, Not yet reported Tanta University 70 participants Est. completion 2027-03-30
  Other conditions: Poly Cystic Ovary Syndrome
  View official trial listing →

Not yet reported.

Not yet reported.

• ClinicalTrials.gov — NCT04410341

No related coverage yet.